| 货号 | HB997036 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 同种型 | IgG |
|---|
| 克隆号 | MK-1966 |
|---|
| 生物活性 | MK-1966 strongly induces IFNγ production in human PBMCs when combined with the TLR9 agonist SD-101 [1]. MK-1966 (10 ug/mL; 24 h) restores CD8 + T-cell proliferation and functional cytokine production that is suppressed by COL4A1-induced M2-like macrophages [2]. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 经测试应用 | FCM |
|---|
| 靶标 | IL-10, IL10, Cytokine synthesis inhibitory factor, CSIF, Interleukin-10 |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | P22301 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | MK-1966, MK1966, MK1966 |
|---|
| 背景 | Interleukin-10 (IL10) is a ~20 kDa protein. Major immune regulatory cytokine that acts on many cells of the immune system where it has profound anti-inflammatory functions, limiting excessive tissue disruption caused by inflammation. Mechanistically, IL10 binds to its heterotetrameric receptor comprising IL10RA and IL10RB leading to JAK1 and STAT2-mediated phosphorylation of STAT3. In turn, STAT3 translocates to the nucleus where it drives expression of anti-inflammatory mediators. Targets antigen-presenting cells (APCs) such as macrophages and monocytes and inhibits their release of pro-inflammatory cytokines including granulocyte-macrophage colony-stimulating factor /GM-CSF, granulocyte colony-stimulating factor/G-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8 and TNF. Also interferes with antigen presentation by reducing the expression of MHC-class II and co-stimulatory molecules, thereby inhibiting their ability to induce T cell activation. 1. Yoon, SI. et al. (2006) The Journal of biological chemistry 281, 35088-96. PMID: 169826082. El Kasmi, KC. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 7215-9. PMID: 180251623. Hashimoto, SI. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 3619-25. PMID: 115647744. de Waal Malefyt, R. et al. (1991) The Journal of experimental medicine 174, 1209-20. PMID: 19407995. Willems, F. et al. (1994) European journal of immunology 24, 1007-9. PMID: 75120276. Frei, K. et al. (1994) Journal of immunology (Baltimore, Md. : 1950) 152, 2720-8. PMID: 8144879 |
|---|
| 文献 | 1. Phan U, et al. Development of the anti-IL-10 mAb MK-1966 in combination with in situ vaccination of a TLR9 agonist SD-101 for cancer immunotherapy[J]. European Journal of Cancer, 2016, 69: S91-S92. [HB997036]
2. Chen J, et al. CD146+ CAFs mediate immunosuppression in gastric cancer via COL4A1: potential therapeutic targets. J Immunother Cancer. 2025;13(12):e013577. Published 2025 Dec 21. [HB997036] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
|---|
